[Prostate cancer patients with lymph node metastasis. Outcome in a consecutive group of 59 patients]
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
[Prostate cancer patients with lymph node metastasis. Outcome in a consecutive group of 59 patients]. / Roder, M.A.; Reinhardt, S.; Brasso, K.; Iversen, P.
I: Ugeskrift for læger, Bind 170, Nr. 34, 2008, s. 2554-2558.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - [Prostate cancer patients with lymph node metastasis. Outcome in a consecutive group of 59 patients]
AU - Roder, M.A.
AU - Reinhardt, S.
AU - Brasso, K.
AU - Iversen, P.
PY - 2008
Y1 - 2008
N2 - INTRODUCTION: The optimal management of prostate cancer patients with lymph node metastasis remains controversial. In this article, the outcome in a consecutive group of patients with newly diagnosed lymph node positive prostate cancer is presented. MATERIALS AND METHODS: In 59 patients with histological verified lymph node positive disease but without osseous metastasis, outcome is described by time to biochemical progression, time to metastasis and survival. RESULTS: Median age at diagnosis was 62 years. Median pre-treatment PSA was 21 ng/ml. Endocrine treatment was initiated within median 2 weeks in 97% of the patients. Median follow-up was 3 years. Median time to biochemical progression was 1.8 years and 5-year biochemical recurrence-free survival was 14%. Median time to development of osseous metastasis was 4.4 years and 5-year metastasis-free survival was 49%. Eighteen of the 59 patients died during follow-up, 15 deaths were attributable to prostate cancer. Estimated median survival was 5.5 years. CONCLUSION: Despite early androgen deprivation therapy, patients with lymph node positive prostate cancer have a grave prognosis with a high risk of progression and disease-specific mortality Udgivelsesdato: 2008/8/18
AB - INTRODUCTION: The optimal management of prostate cancer patients with lymph node metastasis remains controversial. In this article, the outcome in a consecutive group of patients with newly diagnosed lymph node positive prostate cancer is presented. MATERIALS AND METHODS: In 59 patients with histological verified lymph node positive disease but without osseous metastasis, outcome is described by time to biochemical progression, time to metastasis and survival. RESULTS: Median age at diagnosis was 62 years. Median pre-treatment PSA was 21 ng/ml. Endocrine treatment was initiated within median 2 weeks in 97% of the patients. Median follow-up was 3 years. Median time to biochemical progression was 1.8 years and 5-year biochemical recurrence-free survival was 14%. Median time to development of osseous metastasis was 4.4 years and 5-year metastasis-free survival was 49%. Eighteen of the 59 patients died during follow-up, 15 deaths were attributable to prostate cancer. Estimated median survival was 5.5 years. CONCLUSION: Despite early androgen deprivation therapy, patients with lymph node positive prostate cancer have a grave prognosis with a high risk of progression and disease-specific mortality Udgivelsesdato: 2008/8/18
M3 - Tidsskriftartikel
VL - 170
SP - 2554
EP - 2558
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 34
ER -
ID: 14276211